128 related articles for article (PubMed ID: 38479497)
1. Safety and efficacy of levosimendan in patients with cardiac amyloidosis.
Aimo A; Arzilli C; Castiglione V; Morfino P; Panichella G; Passino C; Vergaro G; Emdin M
Int J Cardiol; 2024 Jun; 405():131963. PubMed ID: 38479497
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial.
Comín-Colet J; Manito N; Segovia-Cubero J; Delgado J; García Pinilla JM; Almenar L; Crespo-Leiro MG; Sionis A; Blasco T; Pascual-Figal D; Gonzalez-Vilchez F; Lambert-Rodríguez JL; Grau M; Bruguera J;
Eur J Heart Fail; 2018 Jul; 20(7):1128-1136. PubMed ID: 29405611
[TBL] [Abstract][Full Text] [Related]
3. Short-term efficacy and safety of levosimendan in patients with chronic systolic heart failure.
Cui XR; Yang XH; Li RB; Wang D; Jia M; Bai L; Zhang JD
Cardiovasc J Afr; 2020; 31(4):196-200. PubMed ID: 32555927
[TBL] [Abstract][Full Text] [Related]
4. [Safety and efficacy of the early administration of levosimendan in patients with acute non-ST-segment elevation myocardial infarction and elevated NT-proBNP levels: An Early Management Strategy of Acute Heart Failure (EMS-AHF)].
Xu F; Bian Y; Zhang GQ; Gao LY; Liu YF; Liu TX; Li G; Song RX; Su LJ; Zhou YJ; Cui JY; Yan XL; Guo FM; Zhang HY; Li QH; Zhao M; Ma LK; You BA; Wang G; Kong L; Ma JL; Zhou XF; Chang ZL; Tang ZY; Yu DY; Cheng K; Xue L; Li X; Pang JJ; Wang JL; Zhang HT; Yu XZ; Chen YG
Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):374-383. PubMed ID: 37032132
[No Abstract] [Full Text] [Related]
5. Haemodynamic effects of levosimendan in advanced but stable chronic heart failure.
Najjar E; Stålhberg M; Hage C; Ottenblad E; Manouras A; Haugen Löfman I; Lund LH
ESC Heart Fail; 2018 Jun; 5(3):302-308. PubMed ID: 29469177
[TBL] [Abstract][Full Text] [Related]
6. Levosimendan Can Improve the Level of B-Type Natriuretic Peptide and the Left Ventricular Ejection Fraction of Patients with Advanced Heart Failure: A Meta-analysis of Randomized Controlled Trials.
Cui D; Liao Y; Li G; Chen Y
Am J Cardiovasc Drugs; 2021 Jan; 21(1):73-81. PubMed ID: 32462455
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety of levosimendan in elderly patients with severe heart failure].
Wang YB; Yu YH; Gong SJ; Yan J; Wang Y
Zhonghua Nei Ke Za Zhi; 2020 Jun; 59(6):433-438. PubMed ID: 32486583
[No Abstract] [Full Text] [Related]
8. Effects of Levosimendan on cardiac function, size and strain in heart failure patients.
Beitzke D; Gremmel F; Senn D; Laggner R; Kammerlander A; Wielandner A; Nolz R; Hülsmann M; Loewe C
Int J Cardiovasc Imaging; 2021 Mar; 37(3):1063-1071. PubMed ID: 33103224
[TBL] [Abstract][Full Text] [Related]
9. Multicenter experiences with levosimendan therapy and its safety in patients with decompensated advanced heart failure.
Lelonek M; Stopczyńska I; Korościk E; Straburzyńska-Migaj E; Gruchała M
Adv Clin Exp Med; 2020 Nov; 29(11):1305-1312. PubMed ID: 33269816
[TBL] [Abstract][Full Text] [Related]
10. Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment:A Randomized Double-Blind Controlled Trial.
Lannemyr L; Ricksten SE; Rundqvist B; Andersson B; Bartfay SE; Ljungman C; Dahlberg P; Bergh N; Hjalmarsson C; Gilljam T; Bollano E; Karason K
J Am Heart Assoc; 2018 Aug; 7(16):e008455. PubMed ID: 30369310
[TBL] [Abstract][Full Text] [Related]
11. Levosimendan in decompensated heart failure patients: efficacy in a Brazilian cohort. Results of the BELIEF study.
Bocchi EA; Vilas-Boas F; Moreira Mda C; Barretto AC; Lage S; Albuquerque D; Baima J; Rassi S; Ribeiro JP; ;
Arq Bras Cardiol; 2008 Mar; 90(3):182-90. PubMed ID: 18392398
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).
Moiseyev VS; Põder P; Andrejevs N; Ruda MY; Golikov AP; Lazebnik LB; Kobalava ZD; Lehtonen LA; Laine T; Nieminen MS; Lie KI;
Eur Heart J; 2002 Sep; 23(18):1422-32. PubMed ID: 12208222
[TBL] [Abstract][Full Text] [Related]
13. Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction.
Hou ZQ; Sun ZX; Su CY; Tan H; Zhong X; Hu B; Zhou Y; Shang DY
Cardiovasc Ther; 2013 Apr; 31(2):108-14. PubMed ID: 23490237
[TBL] [Abstract][Full Text] [Related]
14. Levosimendan in outpatients with advanced heart failure: Single-center experience of 200 intermittent perfusions.
Ferreira Reis J; Valentim Gonçalves A; Ilhão Moreira R; Pereira da Silva T; Timóteo AT; Pombo D; Carvalho T; Correia C; Santos C; Cruz Ferreira R
Rev Port Cardiol; 2023 Apr; 42(4):335-343. PubMed ID: 36634758
[TBL] [Abstract][Full Text] [Related]
15. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
[TBL] [Abstract][Full Text] [Related]
16. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period.
Pölzl G; Allipour Birgani S; Comín-Colet J; Delgado JF; Fedele F; García-Gonzáles MJ; Gustafsson F; Masip J; Papp Z; Störk S; Ulmer H; Vrtovec B; Wikström G; Altenberger J
ESC Heart Fail; 2019 Feb; 6(1):174-181. PubMed ID: 30378288
[TBL] [Abstract][Full Text] [Related]
17. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period: The multinational randomized LeoDOR trial.
Pölzl G; Altenberger J; Comín-Colet J; Delgado JF; Fedele F; García-González MJ; Gustafsson F; Masip J; Papp Z; Störk S; Ulmer H; Maier S; Vrtovec B; Wikström G; Zima E; Bauer A;
Eur J Heart Fail; 2023 Nov; 25(11):2007-2017. PubMed ID: 37634941
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of simendan in the treatment of acute heart failure and its impact on NT-proBNP.
Li J; Wang XY; Yang ZY; Li Y; Yang F; Yuan P; Yang J
Eur Rev Med Pharmacol Sci; 2019 May; 23(9):4027-4032. PubMed ID: 31115032
[TBL] [Abstract][Full Text] [Related]
19. [Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure].
Tek M; Cavuşoğlu Y; Demirüstü C; Birdane A; Ünalır A; Görenek B; Göktekin Ö; Ata N
Turk Kardiyol Dern Ars; 2010 Jul; 38(5):334-40. PubMed ID: 21200103
[TBL] [Abstract][Full Text] [Related]
20. Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery.
Mehta RH; Leimberger JD; van Diepen S; Meza J; Wang A; Jankowich R; Harrison RW; Hay D; Fremes S; Duncan A; Soltesz EG; Luber J; Park S; Argenziano M; Murphy E; Marcel R; Kalavrouziotis D; Nagpal D; Bozinovski J; Toller W; Heringlake M; Goodman SG; Levy JH; Harrington RA; Anstrom KJ; Alexander JH;
N Engl J Med; 2017 May; 376(21):2032-2042. PubMed ID: 28316276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
